MICAFUNGIN SODIUM

Post-LOE

micafungin sodium

Hikma

ANDAINTRAVENOUSINJECTABLE

Approved

Jul 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MICAFUNGIN SODIUM (micafungin sodium) by Hikma is 12. Approved for echinocandin antifungal [epc], acute disseminated candidiasis, abscesses in adult and 1 more indications. First approved in 2021.

Drug data last refreshed 20h ago

Mechanism of Action

12.1 Mechanism of Action Micafungin is a member of the echinocandin class of antifungal agents [see ] . 12.2 Pharmacodynamics The pharmacodynamics of micafungin related to hematogenous Candida meningoencephalitis are described in other sections of the prescribing information [see ) and )]. 12.3…

Worked on MICAFUNGIN SODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MICAFUNGIN SODIUM

Mechanism of Action

Indications (3)

Clinical Trials (1)